Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.
Methods Mol Biol. 2022;2521:67-83. doi: 10.1007/978-1-0716-2441-8_4.
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own immune cells with antigen-specific receptors has shown remarkable efficacy in blood cancer treatment. Numerous clinical studies with CAR T cells targeting the blood cell surface protein CD19 led to the FDA 's first approval of a genetically engineered cell therapy. The process of generating potent CAR T cells involves several carefully performed manufacturing steps. Here, we describe the generation of redirected engineered human CAR T cells for preclinical studies starting with the CAR design, retroviral gene transfer, detection of CAR expression, and expansion of transduced T cells.
嵌合抗原受体 (CAR) T 细胞疗法通过基因工程将患者自身的免疫细胞与抗原特异性受体结合，已在血液癌症治疗中显示出显著疗效。许多针对血细胞表面蛋白 CD19 的 CAR T 细胞的临床研究导致 FDA 首次批准了一种基因工程细胞疗法。生成有效 CAR T 细胞的过程涉及几个精心执行的制造步骤。在这里，我们从 CAR 设计、逆转录病毒基因转移、CAR 表达检测和转导 T 细胞的扩增开始，描述了用于临床前研究的定向工程人类 CAR T 细胞的生成。
